NKTR Drug delivery Company Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NKTR Drug delivery Company

NKTR 53.98

-6.5%

Nov 13 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: david nordic who wrote (185)	4/13/2007 12:27:52 PM
From: tuck	Read Replies (1) of 507

Exubera patent fight news >>Novo Nordisk scales back patent suit against Pfizer to two cases - report April 11, 2007: 08:38 AM EST Apr. 11, 2007 (AFX International Focus) -- COPENHAGEN (Thomson Financial) - Novo Nordisk (NYSE:NVO) has decided to reduce the scope of its ongoing patent suit against Pfizer (NYSE:PFE) Inc to the two most important patents at issue, rather than the original five, RB Borsen said, citing Novo Nordisk Vice President Mike Rulis. Novo Nordisk filed a lawsuit against Pfizer last year, claiming the US group's Exubera drug infringes on its patent covering inhaled insulin treatment for diabetes. 'We believe we still have a very strong case,' Rulis said, adding that he expects the issue to be resolved by next summer at the earliest.<< Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next